These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21803099)

  • 1. Malaria vaccine candidate: design of a multivalent subunit α-helical coiled coil poly-epitope.
    Olugbile S; Villard V; Bertholet S; Jafarshad A; Kulangara C; Roussilhon C; Frank G; Agak GW; Felger I; Nebie I; Konate K; Kajava AV; Schuck P; Druilhe P; Spertini F; Corradin G
    Vaccine; 2011 Sep; 29(40):7090-9. PubMed ID: 21803099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmodium vivax antigen discovery based on alpha-helical coiled coil protein motif.
    Céspedes N; Habel C; Lopez-Perez M; Castellanos A; Kajava AV; Servis C; Felger I; Moret R; Arévalo-Herrera M; Corradin G; Herrera S
    PLoS One; 2014; 9(6):e100440. PubMed ID: 24959747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of adjuvants in inducing immune responses to different epitopes included in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice.
    Rafi-Janajreh A; Tongren JE; Kensil C; Hackett C; Candal F; Lal A; Udhayakumar V
    Exp Parasitol; 2002 May; 101(1):3-12. PubMed ID: 12243733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.
    Balam S; Jafarshad A; Servis C; Frank G; Reed S; Pink R; Druilhe P; Spertini F; Corradin G
    Vaccine; 2016 Mar; 34(13):1566-1574. PubMed ID: 26874325
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ayadi I; Balam S; Audran R; Bikorimana JP; Nebie I; Diakité M; Felger I; Tanner M; Spertini F; Corradin G; Arevalo M; Herrera S; Agnolon V
    Front Immunol; 2020; 11():574330. PubMed ID: 33193361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and Characterisation of a Key Epitope in the Conserved C-Terminal Domain of the Malaria Vaccine Candidate MSP2.
    Seow J; Morales RA; MacRaild CA; Krishnarjuna B; McGowan S; Dingjan T; Jaipuria G; Rouet R; Wilde KL; Atreya HS; Richards JS; Anders RF; Christ D; Drinkwater N; Norton RS
    J Mol Biol; 2017 Mar; 429(6):836-846. PubMed ID: 28189425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology.
    Okitsu SL; Mueller MS; Amacker M; Vogel D; Westerfeld N; Robinson JA; Zurbriggen R; Pluschke G
    Hum Vaccin; 2008; 4(2):106-14. PubMed ID: 18382133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
    de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
    Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for antibody recognition of the NANP repeats in
    Oyen D; Torres JL; Wille-Reece U; Ockenhouse CF; Emerling D; Glanville J; Volkmuth W; Flores-Garcia Y; Zavala F; Ward AB; King CR; Wilson IA
    Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10438-E10445. PubMed ID: 29138320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic peptides based on conserved Plasmodium falciparum antigens are immunogenic and protective against Plasmodium yoelii malaria.
    Chauhan VS; Chatterjee S; Johar PK
    Parasite Immunol; 1993 Apr; 15(4):239-42. PubMed ID: 7685076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-clinical assessment of novel multivalent MSP3 malaria vaccine constructs.
    Bang G; Prieur E; Roussilhon C; Druilhe P
    PLoS One; 2011; 6(12):e28165. PubMed ID: 22145028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors.
    Lopez JA; Roggero MA; Duombo O; Gonzalez JM; Tolle R; Koita O; Arevalo-Herrera M; Herrera S; Corradin G
    Am J Trop Med Hyg; 1996 Oct; 55(4):424-9. PubMed ID: 8916800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fine specificity of immune responses to epitopic sequences in synthetic peptides containing B and T epitopes from the conserved Plasmodium falciparum blood-stage antigens.
    Chatterjee S; Sharma P; Kumar S; Chauhan VS
    Vaccine; 1995; 13(15):1474-81. PubMed ID: 8578829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.
    Birkett A; Lyons K; Schmidt A; Boyd D; Oliveira GA; Siddique A; Nussenzweig R; Calvo-Calle JM; Nardin E
    Infect Immun; 2002 Dec; 70(12):6860-70. PubMed ID: 12438363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c.
    Olugbile S; Kulangara C; Bang G; Bertholet S; Suzarte E; Villard V; Frank G; Audran R; Razaname A; Nebie I; Awobusuyi O; Spertini F; Kajava AV; Felger I; Druilhe P; Corradin G
    Infect Immun; 2009 Dec; 77(12):5701-9. PubMed ID: 19786562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity.
    Theisen M; Dodoo D; Toure-Balde A; Soe S; Corradin G; Koram KK; Kurtzhals JA; Hviid L; Theander T; Akanmori B; Ndiaye M; Druilhe P
    Infect Immun; 2001 Sep; 69(9):5223-9. PubMed ID: 11500389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of protective CD8
    Quadiri A; Kalia I; Kashif M; Singh AP
    Immun Inflamm Dis; 2020 Mar; 8(1):50-61. PubMed ID: 31967737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein structure based strategies for antigen discovery and vaccine development against malaria and other pathogens.
    Corradin G; Villard V; Kajava AV
    Endocr Metab Immune Disord Drug Targets; 2007 Dec; 7(4):259-65. PubMed ID: 18220946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural immune response to Plasmodium vivax alpha-helical coiled coil protein motifs and its association with the risk of P. vivax malaria.
    Céspedes N; Li Wai Suen CSN; Koepfli C; França CT; Felger I; Nebie I; Arévalo-Herrera M; Mueller I; Corradin G; Herrera S
    PLoS One; 2017; 12(6):e0179863. PubMed ID: 28651021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.